NCT03040362View on ClinicalTrials.gov

Absorption, Metabolism and Excretion of [14C]-Lasmiditan - Single Oral Dose Administration

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

April 20, 2017

Primary Completion Date

May 6, 2017

Study Completion Date

May 6, 2017

Conditions

Healthy

Interventions

DRUG

[14C]-lasmiditan

\[14C\]-lasmiditan as a 200 mg (approximately 100 µCi) oral solution

Trial Locations (1)

53704

Covance Clinical Research Unit, Madison

Sponsors

Collaborators (1)

CoLucid Pharmaceuticals

All Listed Sponsors

collaborator

CoLucid Pharmaceuticals

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT03040362 - Absorption, Metabolism and Excretion of [14C]-Lasmiditan - Single Oral Dose Administration | Biotech Hunter | Biotech Hunter